Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Replication-selective viruses for cancer therapy.

Carola Biederer1, Stefan Ries, Christian H Brandts

  • 1SWITCH Biotech AG, Fraunhofer Strasse 10, 82152 Martinsried, Germany.

Journal of Molecular Medicine (Berlin, Germany)
|March 15, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NF1 and SPRED1/2 cooperate through RAS-MAPK-independent functions.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRAS<sup>G12C</sup> suppresses PI3Kα and leads to potent tumor inhibition.

bioRxiv : the preprint server for biology·2026
Same author

Revisiting RAS family GTPase signaling: effector selectivity and oncogenic bypass.

The Biochemical journal·2026
Same author

Inhibition of high CXCR4 with Motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

Blood·2026
Same author

Multi-layered molecular profiling informs the diagnosis and targeted therapy of desmoplastic small round cell tumor.

Nature communications·2026
Same author

Dashboard Knee: Injury Mechanisms, Diagnostic Challenges, and Treatment Outcomes.

Cureus·2026
Same journal

Integrative genetic and functional analysis of autosomal dominant hearing loss in 108 multigenerational families.

Journal of molecular medicine (Berlin, Germany)·2026
Same journal

Preclinical evaluation of cysteine protease-inhibitor aloxistatin (E64d) for heart failure therapy.

Journal of molecular medicine (Berlin, Germany)·2026
Same journal

Zinc-binding protein metallothionein 3 protects vascular smooth muscle cells from ferroptosis via blocking lysosomal degradation of GPX4.

Journal of molecular medicine (Berlin, Germany)·2026
Same journal

Clinical utility of cerebrospinal fluid interleukin-10 in central nervous system lymphoma: a molecular neuropathology-informed diagnostic meta-analysis.

Journal of molecular medicine (Berlin, Germany)·2026
Same journal

Molecular regulation of PGC-1α: from protein-protein interactions and post-translational modifications to pharmacological modulation.

Journal of molecular medicine (Berlin, Germany)·2026
Same journal

Molecular determinants of thromboinflammatory activation in inflammatory bowel disease.

Journal of molecular medicine (Berlin, Germany)·2026
See all related articles

Replication-selective viruses are engineered to target and kill cancer cells, offering a promising new avenue for tumor therapy. ONYX-015, an adenovirus, shows encouraging early clinical trial results in cancer treatment.

Area of Science:

  • Oncology
  • Virology
  • Molecular Biology

Background:

  • Advances in cancer molecular biology and genetic engineering enable the development of oncolytic viruses.
  • Replication-selective viruses offer targeted cancer cell killing and self-amplification of therapeutic effect.

Purpose of the Study:

  • To review strategies for cancer cell killing based on molecular defects.
  • To discuss progress in tumor therapy using replication-competent viruses.

Main Methods:

  • Review of preclinical data from tissue culture and animal models.
  • Analysis of accumulating clinical data from first-generation replication-selective viruses.
  • Focus on a specific replication-selective adenovirus, ONYX-015.

Main Results:

Related Experiment Videos

  • Preclinical studies support the efficacy of replication-selective viruses.
  • Early clinical trials with ONYX-015 show encouraging results.
  • Therapeutic success depends on host and viral factors.

Conclusions:

  • Replication-competent viruses represent a developing strategy for cancer treatment.
  • Further clinical evaluation is necessary to determine the therapeutic index and outcomes.
  • Understanding host-viral interactions is key to optimizing oncolytic virotherapy.